{
    "clinical_study": {
        "@rank": "62274", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effectiveness of naltrexone (Revia) in\n      reducing drinking and smoking in patients with both nicotine and alcohol dependence.\n\n      Individuals will be randomly assigned to a 12-week trial of a fixed daily dose of either\n      naltrexone (Revia) and nicotine replacement patch or placebos.  All individuals will receive\n      weekly coping skills and smoking-cessation behavioral therapy.  Followup interviews will be\n      conducted 3 and 6 months after treatment to determine smoking and drinking status and\n      persistence of any dependence symptoms."
        }, 
        "brief_title": "Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)", 
        "completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Alcoholism", 
            "Smoking"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alcoholism", 
                "Smoking", 
                "Tobacco Use Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets criteria for alcohol dependence and nicotine dependence.\n\n          -  Expresses a desire to cut down or stop drinking and smoking.\n\n        Exclusion Criteria:\n\n          -  Currently meets criteria for dependence on substances other than alcohol and\n             nicotine.\n\n          -  Any history of opiate dependence or evidence of current opiate use.\n\n          -  Significant medical disorders that will increase potential risk or interfere with\n             study participation.\n\n          -  Liver function tests more than 3 times normal or elevated bilirubin.\n\n          -  Females who are pregnant, nursing, or not using a reliable method of birth control.\n\n          -  Meets criteria for a major psychiatric disorder and is in need of or currently\n             undergoing drug therapy.\n\n          -  Inability to understand and/or comply with the provisions of the protocol and consent\n             form.\n\n          -  Treatment with an investigational drug during the previous month.\n\n          -  Chronic treatment with any narcotic-containing medications during the previous month.\n\n          -  Sensitivity to drug as evidenced by adverse drug experiences especially with\n             narcotic- containing analgesics or opioid antagonists.\n\n          -  Current treatment with disulfiram (Antabuse) or nicotine replacement therapy.\n\n          -  More than 6 weeks of abstinence."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "166", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000437", 
            "org_study_id": "NIAAAMAS11210", 
            "secondary_id": "R01AA011210"
        }, 
        "intervention": [
            {
                "intervention_name": "naltrexone (Revia)", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "nicotine replacement patch", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naltrexone", 
                "Nicotine polacrilex", 
                "Nicotine"
            ]
        }, 
        "lastchanged_date": "July 21, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "Department of Psychiatry, University of Miami School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Nalmefene in Nicotine and Alcohol Dependence", 
        "overall_official": {
            "affiliation": "University of Miam", 
            "last_name": "Barbara Mason, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000437"
        }, 
        "source": "The Scripps Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "The Scripps Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2010"
    }, 
    "geocoordinates": {
        "Department of Psychiatry, University of Miami School of Medicine": "25.789 -80.226"
    }
}